phone

Atrial Fibrillation - Pipeline Review, H2 2017

  • Published Date: 08 Aug 2017
  • Number of Pages: 88
  • Category: Healthcare and Medical
  • Country: Global
Atrial Fibrillation - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Atrial Fibrillation - Pipeline Review, H2 2017, provides an overview of the Atrial Fibrillation (Cardiovascular) pipeline landscape.

Atrial fibrillation is an irregular and often rapid heart rate that commonly causes poor blood flow to the body. Symptoms include decreased blood pressure, weakness, lightheadedness, confusion and chest pain. The predisposing factors include age, heart disease, high blood pressure, family history and drinking alcohol. Treatments for atrial fibrillation may include medications and surgery.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Atrial Fibrillation - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Atrial Fibrillation (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atrial Fibrillation (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Atrial Fibrillation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3, 2, 8 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.

Atrial Fibrillation (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Atrial Fibrillation (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Atrial Fibrillation (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Atrial Fibrillation (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Atrial Fibrillation (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Atrial Fibrillation (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Atrial Fibrillation (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Atrial Fibrillation (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Publisher Name : Global Markets Direct

Introduction 5
Global Markets Direct Report Coverage 5
Atrial Fibrillation - Overview 6
Atrial Fibrillation - Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Pipeline by Universities/Institutes 9
Products under Development by Companies 10
Products under Development by Universities/Institutes 11
Atrial Fibrillation - Therapeutics Assessment 12
Assessment by Target 12
Assessment by Mechanism of Action 14
Assessment by Route of Administration 16
Assessment by Molecule Type 18
Atrial Fibrillation - Companies Involved in Therapeutics Development 20
Acesion Pharma Aps 20
ARCA biopharma Inc 20
Armetheon Inc 21
AstraZeneca Plc 21
Bristol-Myers Squibb Company 22
Cardiome Pharma Corp 22
Daiichi Sankyo Company Ltd 23
Dong-A Socio Holdings Co Ltd 23
Gilead Sciences Inc 24
InCarda Therapeutics Inc 24
Merck & Co Inc 25
N-Gene Research Laboratories Inc 25
Nissan Chemical Industries Ltd 26
OMEICOS Therapeutics GmbH 26
Verseon Corp 27
Atrial Fibrillation - Drug Profiles 28
AFC-1 - Drug Profile 28
BGP-15 - Drug Profile 29
BMS-919373 - Drug Profile 31
bucindolol hydrochloride - Drug Profile 32
budiodarone - Drug Profile 39
edoxaban tosylate - Drug Profile 41
flecainide acetate - Drug Profile 47
GBCA-1 - Drug Profile 49
Gene Therapy for Atrial Fibrillation - Drug Profile 50
GS-967 - Drug Profile 51
Heparin - Drug Profile 52
MK-1832 - Drug Profile 53
NIP-151 - Drug Profile 54
NYK-1112 - Drug Profile 56
OMT-28 - Drug Profile 57
Small Molecule to Block Calcium Activated Potassium Channel for Atrial Fibrillation - Drug Profile 58
Small Molecule to Block Kv1.5 for Atrial Fibrillation - Drug Profile 59
Small Molecules to Block GIRK for Atrial Fibrillation - Drug Profile 60
Small Molecules to Inhibit CaMKII for Arrhythmias and Heart Failure - Drug Profile 61
Small Molecules to Inhibit Thrombin for Cardiovascular Diseases - Drug Profile 62
vernakalant hydrochloride - Drug Profile 64
Atrial Fibrillation - Dormant Projects 69
Atrial Fibrillation - Discontinued Products 72
Atrial Fibrillation - Product Development Milestones 74
Featured News & Press Releases 74
Appendix 85
Methodology 85
Coverage 85
Secondary Research 85
Primary Research 85
Expert Panel Validation 85
Contact Us 85
Disclaimer 86

List Of Tables


Number of Products under Development for Atrial Fibrillation, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Atrial Fibrillation - Pipeline by Acesion Pharma Aps, H2 2017
Atrial Fibrillation - Pipeline by ARCA biopharma Inc, H2 2017
Atrial Fibrillation - Pipeline by Armetheon Inc, H2 2017
Atrial Fibrillation - Pipeline by AstraZeneca Plc, H2 2017
Atrial Fibrillation - Pipeline by Bristol-Myers Squibb Company, H2 2017
Atrial Fibrillation - Pipeline by Cardiome Pharma Corp, H2 2017
Atrial Fibrillation - Pipeline by Daiichi Sankyo Company Ltd, H2 2017
Atrial Fibrillation - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2017
Atrial Fibrillation - Pipeline by Gilead Sciences Inc, H2 2017
Atrial Fibrillation - Pipeline by InCarda Therapeutics Inc, H2 2017
Atrial Fibrillation - Pipeline by Merck & Co Inc, H2 2017
Atrial Fibrillation - Pipeline by N-Gene Research Laboratories Inc, H2 2017
Atrial Fibrillation - Pipeline by Nissan Chemical Industries Ltd, H2 2017
Atrial Fibrillation - Pipeline by OMEICOS Therapeutics GmbH, H2 2017
Atrial Fibrillation - Pipeline by Verseon Corp, H2 2017
Atrial Fibrillation - Dormant Projects, H2 2017
Atrial Fibrillation - Dormant Projects, H2 2017 (Contd..1), H2 2017
Atrial Fibrillation - Dormant Projects, H2 2017 (Contd..2), H2 2017
Atrial Fibrillation - Discontinued Products, H2 2017
Atrial Fibrillation - Discontinued Products, H2 2017 (Contd..1), H2 2017

List Of Figures


Number of Products under Development for Atrial Fibrillation, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

Atrial Fibrillation - Pipeline Review, H2 2017 Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Atrial Fibrillation - Pipeline Review, H2 2017, provides an overview of the Atrial Fibrillation

View Report

Atrial Fibrillation Global Clinical Trials Review, H1, 2017 GlobalDatas clinical trial report, Atrial Fibrillation Global Clinical Trials Review, H1, 2017 provides an overview of Atrial Fibrillation clinical trials scenario. This report

View Report

Atrial Flutter Global Clinical Trials Review, H1, 2017 GlobalDatas clinical trial report, Atrial Flutter Global Clinical Trials Review, H1, 2017 provides an overview of Atrial Flutter clinical trials scenario. This report

View Report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports